Jacob Kimmel

In this enlightening conversation, Jacob Kimmel, Co-founder and President of NewLimit, shares his groundbreaking work in reversing aging through epigenetic reprogramming. He discusses why evolution hasn't optimized for longevity and the complexities of drug discovery. The chat delves into the role of transcription factors in rejuvenating cells and innovative gene delivery methods that could transform medical treatments. Kimmel also offers intriguing insights into CAR-T cell therapy and how biotech innovations may revolutionize healthcare.

Jacob Kimmel, co-founder and president of New Limit, shares insights into revolutionary biotech aimed at reprogramming cellular aging. He discusses their groundbreaking work with transcription factors, which can potentially restore youthful cell functions. Exciting advancements in epigenetic reprogramming are revealed, including successes in rejuvenating old liver cells. Kimmel emphasizes the collaboration between academia and industry driving progress in longevity science, and the challenges faced in gene manipulation as they seek to enhance human health and lifespan.

Jacob Kimmel, co-founder and president of New Limit, dives into the revolutionary world of longevity medicine, exploring the future of epigenetic reprogramming and its potential to enhance health and lifespan. Sam Lessin of Slow Ventures shares insights on OpenAI's competitive hiring platform, discussing the evolving skills needed in entrepreneurship and the tech landscape. The conversation also touches on the rising popularity of GLP-1 medications in Silicon Valley, highlighting not just weight loss benefits but broader lifestyle impacts, all set against the backdrop of the shifting enterprise software market.